There are currently 224 clinical trials in Santa Monica, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Clinical Science Institute, Sarcoma Oncology Center, Citruslabs and John Wayne Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Linking Churches With Parks to Increase Physical Activity Among Latinos
NCT03858868
Recruiting
This study is a cluster randomized controlled trial of a multi-level intervention that links Latino Catholic churches (n=14) with their local parks to increase physical activity among Latino parishioners (n=1204) in Los Angeles. The study will examine the impact of the intervention on Latino parishioners' PA and health-related outcomes; explore differences in the intervention's effectiveness by gender; and evaluate factors associated with implementation for future dissemination. If successful, t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: RAND Corporation, Santa Monica, California
Conditions: Physical Activity
Register for Updates
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
NCT04875702
Recruiting
The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
03/12/2024
Locations: UCLA Health, Santa Monica, California
Conditions: Gout
Register for Updates
Endotypic Traits and Obstructive Sleep Apnea Surgery
NCT05953610
Recruiting
This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).
Gender:
All
Ages:
21 years and above
Trial Updated:
03/11/2024
Locations: UCLA Santa Monica Medical Center, Santa Monica, California
Conditions: Obstructive Sleep Apnea
Register for Updates
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
NCT05511922
Recruiting
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
03/06/2024
Locations: KalVista Investigative Site, Santa Monica, California
Conditions: Hereditary Angioedema
Register for Updates
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
NCT04752813
Recruiting
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: Sarcoma Oncology Research Center, Santa Monica, California
Conditions: Glioblastoma, Glioblastoma Multiforme
Register for Updates
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
NCT05505916
Recruiting
This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/06/2024
Locations: KalVista Investigative Site, Santa Monica, California
Conditions: Hereditary Angioedema
Register for Updates
A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
NCT03972657
Recruiting
The main purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness (ability to treat your cancer) of REGN5678 alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab. The goal of Part 2 (dose expansion) is to use the REGN5678 drug dose(s) found in Part 1 to see how well REGN5678 alone or in com... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: John Wayne Cancer Institute, Santa Monica, California
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Register for Updates
iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction
NCT05870488
Recruiting
STACI is a prospective, multicenter, study of SIJ fusion using the iFuse TORQ implant system.
Gender:
All
Ages:
21 years and above
Trial Updated:
03/05/2024
Locations: Source Healthcare, Santa Monica, California
Conditions: Sacroiliac Joint Dysfunction, Sacroiliac; Fusion, Sacroiliac Disorder, Sacroiliac Joint Pain
Register for Updates
A Study to Investigate LYL797 in Adults With Solid Tumors
NCT05274451
Recruiting
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: University of California, Los Angeles, Santa Monica, California
Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC
Register for Updates
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
NCT05883631
Recruiting
Demonstrate the safety and effectiveness of the Ablacath™ Mapping Catheter and Ablamap® System in patients with all types of atrial fibrillation (AF) including paroxysmal or persistent or long-standing persistent, undergoing and De Novo or Redo procedures. Phenotype patients and demonstrate the prognostication power of Electrographic Flow (EGF®) maps among all subjects using 12-month follow-up outcomes following EGF-guided mapping and ablation.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/28/2024
Locations: Pacific Heart Institute, Santa Monica, California
Conditions: Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Fibrillation Paroxysmal, Arrhythmia, Arrhythmias, Cardiac, Atrial Flutter, Atrial Fibrillation, Paroxysmal or Persistent, Atrial Arrhythmia, Atrial Tachycardia
Register for Updates
A Three-Group Study to Examine the Efficacy of the Air up® Drinking System at Improving Hydration and Associated Health Outcomes
NCT06290479
Recruiting
A randomized, controlled trial evaluating the air up® drinking system's impact on hydration and health outcomes. Participants will use air up® with Peach, Orangeade, or unscented pods and their effects on drinking habits, and health outcomes will be assessed over 12 weeks.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
02/26/2024
Locations: Citruslabs, Santa Monica, California
Conditions: Water Intake
Register for Updates
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823
Recruiting
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California
Conditions: Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
Register for Updates